Table 1.
The association between NLR and HR in cachexia patients
| Neutrophil‐to‐lymphocyte ratio | Model A | Model B | ||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| As continuous (per SD) | 1.34 (1.27–1.40) | <0.001 | 1.22 (1.16–1.29) | <0.001 |
| By NLR cut‐off | ||||
| Low (<3.5) | Ref | Ref | ||
| High (≥3.5) | 1.91 (1.70–2.14) | <0.001 | 1.51 (1.33–1.71) | <0.001 |
| Interquartile | ||||
| Q1 (<1.83) | Ref | Ref | ||
| Q2 (1.8–2.95) | 1.49 (1.23–1.80) | <0.001 | 1.30 (1.08–1.58) | 0.007 |
| Q3 (2.95–4.80) | 1.96 (1.63–2.35) | <0.001 | 1.58 (1.31–1.91) | <0.001 |
| Q4 (≥4.80) | 2.77 (2.31–3.31) | <0.001 | 1.89 (1.56–2.30) | <0.001 |
| P for trend | <0.001 | <0.001 | ||
Model A: Adjusted for gender, age, BMI and TNM stage.
Model B: Adjusted for gender, age, BMI, tumour type, TNM stage, radiotherapy, chemotherapy, KPS score, albumin level, total bilirubin level, red blood cell count, platelet count, hand grip strength, reported reduced food intake, reported anorexia and EORTC QLQ‐C30 score.
BMI, body mass index; EORTC QLQ‐C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C‐30; KPS, Karnofsky Performance Status.